Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX2012Q in Healthy Adults
NCT02015494Phase 1Unknown
- Sponsor
- VaxInnate Corporation
- Start
- Mar 2014
- Primary completion
- Dec 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of VAX2012Q in influenza (7 arms), sponsored by VaxInnate Corporation. Primary endpoint: Safety at 21 days. Status: unknown.
02
Drugs
VAX2012Q
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02015494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015494.